SPK Acquisition Corp. (SPK)
| Previous Close | 10.26 |
| Open | 10.26 |
| Bid | 0.00 x 4000 |
| Ask | 0.00 x 1000 |
| Day's Range | 10.26 - 10.30 |
| 52 Week Range | 9.89 - 10.68 |
| Volume | |
| Avg. Volume | 7,862 |
| Market Cap | 81.051M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
Don't Race Out To Buy Spark New Zealand Limited (NZSE:SPK) Just Because It's Going Ex-Dividend
It looks like Spark New Zealand Limited ( NZSE:SPK ) is about to go ex-dividend in the next four days. Typically, the...
- GlobeNewswire
Varian Biopharmaceuticals, Inc. and SPK Acquisition Corp. Announce Release of Investor Presentation Regarding Previously Announced Merger; Provide Corporate Update
NAPLES, Fla., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Varian Biopharmaceuticals, Inc. (“Varian Bio”), a private, precision oncology company developing novel therapeutics for the treatment of cancer, and SPK Acquisition Corp. (“SPK”) (NASDAQ: SPK), a special purpose acquisition company (“SPAC”), today announced a joint presentation to discuss the proposed transaction and provide a corporate update. The presentation can be accessed by clicking the link here or by visiting Varian Bio’s investor section o
- GlobeNewswire
Varian Biopharmaceuticals, Inc., a Precision Oncology Company, to Become Publicly Traded Through a Merger with SPK Acquisition Corp.
Varian Biopharmaceutical is developing a proprietary atypical protein kinase C iota inhibitor in multiple formulations for a broad range of tumor typesCombined company expected to have a post-transaction pro forma equity value of approximately $116 million, assuming no redemptions from SPK’s existing public shareholdersMerger expected to close in Q2 2022, and the combined company will be listed on NASDAQ under the proposed ticker symbol “VBIO” NAPLES, Fla., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vari
